Omalizumab for management of hypersensitivity reactions to anticancer drugs

Piyush Grover,Matthew Krummenacher,Timothy Loy,Anna K. Nowak,Michaela Lucas
DOI: https://doi.org/10.1111/imj.16464
2024-07-20
Internal Medicine Journal
Abstract:Hypersensitivity reactions to anticancer drugs include treatment‐limiting toxicity. Standard drug desensitisation offers temporary tolerance and hence requires repetition. We used omalizumab, an anti‐immunoglobulin E antibody, to overcome immediate and delayed hypersensitivity reactions to various anticancer drugs. Seven of the eight patients in the current study successfully resumed the desired anticancer drug regimen without standard desensitisation. No safety issues from omalizumab were observed.
medicine, general & internal
What problem does this paper attempt to address?